Cambridge Bioscience is delighted to announce a new distribution partnership with NeoBiotechnologies, bringing the company’s highly validated antibody solutions and immunodetection reagents to researchers, diagnostic laboratories and biopharma organisations across the UK and Ireland.
The partnership will provide scientists with streamlined access to NeoBiotechnologies’ extensive portfolio of monoclonal antibodies, recombinant antibodies, transcription factor antibodies and IHC reagents designed to support applications including immunohistochemistry, flow cytometry and western blotting.
NeoBiotechnologies has established itself as a trusted provider of reliable, highly validated reagents that enable accurate and reproducible results across both research and clinical environments. Through this collaboration, Cambridge Bioscience will offer local technical support, product expertise and responsive customer service to ensure researchers can fully leverage NeoBiotechnologies’ innovative solutions.
This partnership further strengthens Cambridge Bioscience’s commitment to supporting the UK and Ireland life science community with high-quality tools that accelerate scientific discovery and advance biomedical research.
Learn more about NeoBiotechnologies’ portfolio or contact our NeoBiotechnologies specialists.